Semaglutide vs Tirzepatide: Comparing the Heavyweights

For a few years, comparing semaglutide and tirzepatide meant lining up results from separate trials run in different populations, an apples-to-oranges exercise that invited overconfident conclusions. Now there is direct head-to-head evidence: SURMOUNT-5, published in The New England Journal of Medicine in 2025, randomized the two drugs against each other. That changes the quality of the comparison considerably. The short version: tirzepatide produced more weight loss, but the fuller picture involves mechanism, tolerability, and the realities of access and cost.

Two different molecules, two mechanisms

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin release, slow gastric emptying, and reduce appetite through action on the brain.

Tirzepatide is a dual agonist: it engages both the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone, and the prevailing hypothesis is that hitting both pathways produces additive or complementary effects on appetite and metabolism. Whether GIP agonism is the whole explanation for tirzepatide’s larger effect is still being worked out, but the dual-target design is the structural difference between the two drugs. Carrots, vegetables, harvest — illustrating Semaglutide vs Tirzepatide: Comparing the Heavyweights

In SURMOUNT-5, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks. That’s a meaningful finding, but “greater on average” is not “better for every individual,” and the trade-offs deserve equal billing.

What the head-to-head data suggests

Lime, 4k wallpaper, mac wallpaper — illustrating Semaglutide vs Tirzepatide: Comparing the Heavyweights

SURMOUNT-5 enrolled 751 adults with obesity (or overweight with comorbidities) and no diabetes, comparing tirzepatide (10 or 15 mg) against semaglutide (1.7 or 2.4 mg) over 72 weeks. The headline result: tirzepatide cut body weight by 20.2% on average versus 13.7% for semaglutide, roughly 22.8 kg versus 15.0 kg. Waist circumference fell more on tirzepatide too (−18.4 cm vs −13.0 cm). The difference is clinically meaningful, not trivial. Both, it’s worth stressing, deliver weight loss far beyond what earlier-generation agents achieved.

A balanced read of the comparison:

Efficacy (weight loss): tirzepatide came out ahead: 20.2% vs 13.7% in SURMOUNT-5.
Glycemic control: both are highly effective in type 2 diabetes; tirzepatide often shows an edge on blood-sugar endpoints.
Tolerability: both share the class’s GI-dominant side effects (nausea, vomiting, diarrhea, constipation), concentrated during dose escalation. In SURMOUNT-5, GI events leading to discontinuation were somewhat more common on semaglutide (5.6%) than tirzepatide (2.7%). Neither is clearly gentler across the board.
Cardiovascular and outcome data: semaglutide has a longer and deeper outcomes record at this point (including the 17,604-patient SELECT trial showing a 20% relative reduction in major cardiac events), which matters for confidence beyond the scale.

Beyond the trial numbers

Vegetables, fruits, food — illustrating Semaglutide vs Tirzepatide: Comparing the Heavyweights

Real-world choice isn’t decided by effect size alone. Cost, insurance coverage, supply availability, individual tolerability, and specific clinical history all weigh in. A person who tolerates one poorly may do far better on the other, and the “less effective on average” option can be the right one for a given individual.

It’s also worth naming the unknown: long-term comparative outcomes (durability of weight loss after stopping, and head-to-head cardiovascular and other hard endpoints over many years) are still accumulating.

The takeaway

The honest summary is narrower than the headlines. Direct head-to-head evidence (SURMOUNT-5) shows tirzepatide produces more weight loss on average (20.2% vs 13.7%), and that’s a real advantage. But semaglutide carries a deeper cardiovascular outcomes record, the two share a similar side-effect profile, and the best choice for an individual depends on tolerability, cost, access, and clinical context as much as on average efficacy. Both are powerful tools. Neither is a default for everyone, and decisions belong with a clinician who knows the specific case.